Abstract
Research revealed that in vitro activity ofchloroquine and the derivative
molecule of hydroxychloroquine is against the infection caused by the SARS-CoV and
SARS-CoV-2. The US FDA approved the use of both hydroxychloroquinesulfate and
chloroquine phosphate for the critical patients of COVID-19. The clinical trials
supported that the hydroxychloroquine did not substantially reduce the system severity
in non-hospitalized persons. Moreover, it also produces severe side effects like
drowsiness, hypokalaemia, nausea, convulsions, shock, and even death.
Keywords: Controlled randomized trial, COVID-19, Hydroxy chloroquine (HCQ), Post exposure prophylaxis, SARS-CoV-2, Therapy.
Related Journals
Recent Advances in Anti-Infective Drug Discovery
Recent Patents on Anti-Infective Drug Discovery
Current Metabolomics and Systems Biology (Discontinued)
Recent Advances in Inflammation & Allergy Drug Discovery
Current HIV Research
Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry
Infectious Disorders - Drug Targets
Related Books
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in HIV Research
Frontiers in HIV Research
Anthrax: History, Biology, Global Distribution, Clinical Aspects, Immunology, and Molecular Biology
Antiprotozoal Drug Discovery: A Challenge That Remains